Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Karius Diagnostic Test: A Missing Puzzle Piece

Billions upon billions of microbial organisms inhabit the earth and our bodies. When we get sick because of modern-day medicine and technology developments, we can often pinpoint exactly which microbial organisms are the source of the problem. But how, exactly? Karius Chief Technical Officer Sivan Bercovici and Medical Director Dr. Sarah Park joined host David…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Billions upon billions of microbial organisms inhabit the earth and our bodies. When we get sick because of modern-day medicine and technology developments, we can often pinpoint exactly which microbial organisms are the source of the problem. But how, exactly? Karius Chief Technical Officer Sivan Bercovici and Medical Director Dr. Sarah Park joined host David Kemp to talk about the Karius diagnostic test and how it breaks barriers in antimicrobial research.

Karius surfaced out of transplantation research at Stanford, where researchers learned DNA from microbes is sent to the bloodstream and can then be harvested and analyzed. This analysis has two aspects: chemistry, which is capturing as many molecules as possible, and machine learning, which makes sense of the data.

“We all have microbes, and we have mixtures of microbes. And what’s making very hard is that this mixture of microbes or cell-free DNA coming from these microbes, can be similar to one another, they can be similar to other things,” explained Bercovici. “Machine learning had to kick into de-convolute that signal to tell you exactly which microbes you have and exactly what concentration of those microbes,” he continued. Bercovici added, “Unless you apply these algorithms, you end up with a pile of pieces of DNA that are impenetrable for any physician.”

The immunocompromised population is just one example of why diagnostic tests are necessary. With this population, they could have multiple infections due to a lack of immunity. “As a clinician, you really have to think about ‘What test do I order?’” Dr. Park explained. This can be difficult with insurance, which may not agree to cover a test a physician deems necessary, and physicians often end up ordering multiple tests.

“This is where tests like the Karius test can be very useful in conjunction with your other tests to be able to add potentially the answer to the question you’re asking, which is: “What is causing the problem for my patient?’” Dr. Park stated.

With the Karius test, the earlier you use it, the better the results will be, but the results still need to be interpreted in the context of each patient. The test result is not meaningful until put in the context of the patient—what medications they are on, their potential exposures, and other factors. The same microbe detected in patient A will not have the same effect in patient B if their clinical status is different.

“It’s like looking at pieces of a puzzle, and some of the pieces are together, and without the Karius test, we are still missing a huge part of the picture. And hopefully what the Karius test does is fill in more of that picture and make that picture more meaningful so that the clinician can actually use the appropriate antimicrobials, know how to manage the patient better, potentially have that chance to save the patient,” Dr. Park explained.

For more on the Karius diagnostic test and its impact on antimicrobial research and clinical use, visit Spotify, Apple iTunes, YouTube, or www.marketscale.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Health systems are partnering up without changing who owns the hospital

Health systems are partnering up without changing who owns the hospital

Health systems are choosing alliances over mergers, per a July McDermott Will & Schulte analysis and four July deals tracked by Becker's Hospital Review. St. Christopher's, Nemours, Jefferson and Temple signed a nonbinding alliance letter; Palomar UC San Diego Health launched July 1. Ownership stays put; governance, purchasing and outpatient investment absorb the change.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Telemedicine in eye care stops at the retinal scan unless imaging moves home

Telemedicine in eye care stops at the retinal scan unless imaging moves home

An Ophthalmology Times commentary by T.Y. Alvin Liu, Ferdinand Hui and Phillip Phan sorts eye patients into three telemedicine tiers by clinical need. Patients needing regular OCT scans benefit less unless a home device can send the image. Video tools already sit inside Epic and Cerner; the deciding purchase for retina clinics is the imaging device in the patient's living room.

  • 01The dividing line for eye telemedicine is imaging, not video: patients who need regular OCT scans benefit less from remote visits unless a device at home can send the scan, so a video license alone shifts few of those encounters.
  • 02The provider-side requirement, a HIPAA-compliant secured video platform, was already built into Epic and Cerner by 2020; the patient-side requirements (1.5 MB up and down bandwidth, a quiet private room, comfort with the technology) sit outside the health system's control and are the ones worth screening for at scheduling.
  • 03Self-administered home color fundus photography for tracking non-proliferative diabetic retinopathy was named as the nearer route into retina telemedicine; home OCT for wet AMD is the harder gate and the device to watch.

Sep 19, 2026

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512